Status:
COMPLETED
Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98
Lead Sponsor:
ETOP IBCSG Partners Foundation
Conditions:
Breast Cancer
Cognitive/Functional Effects
Eligibility:
FEMALE
30+ years
Phase:
PHASE3
Brief Summary
RATIONALE: Studying cognitive function, such as thinking, attention, concentration, and memory, in postmenopausal women receiving hormone therapy for breast cancer may help improve quality of life and...
Detailed Description
OBJECTIVES: Primary * Compare cognitive function in postmenopausal women with breast cancer who have received 5 years of adjuvant tamoxifen vs letrozole on protocol IBCSG-1-98. Secondary * Compare...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Enrolled in protocol IBCSG-1-98
- Must be in the fifth year of study treatment (i.e., still receiving tamoxifen or letrozole)
- No breast cancer recurrence or second malignancy
- Patients who received 2-4½ years of tamoxifen and have chosen to switch to letrozole to complete 5 years of treatment on protocol IBCSG-1-98 are not eligible
- Hormone receptor status
- Estrogen receptor- and/or progesterone receptor-positive tumor
- PATIENT CHARACTERISTICS:
- Female
- Postmenopausal
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No concurrent hormone replacement therapy
Exclusion
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT00343616
Start Date
April 1 2005
End Date
May 1 2009
Last Update
July 27 2012
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Oncology at Prince of Wales Hospital
Randwick, New South Wales, Australia, 2031
2
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia, 3002
3
St. Vincent's Hospital - Melbourne
Fitzroy, Victoria, Australia, 3065
4
Cabrini Hospital
Malvern, Victoria, Australia, 3144